Drug: BAL101553

Inclusion Criteria:

1. Age = 18 years

2. Patients with either histologically or cytologically confirmed advanced or recurrent
solid tumor, who failed standard therapy or for whom no effective standard therapy is
available.

3. Measurable tumor disease (according to Response Evaluation Criteria in Solid Tumors
[RECIST] v1.1)

4. Life expectancy = 12 weeks

5. Acceptable organ and marrow function at baseline (protocol defined laboratory
parameters)

6. Eastern Cooperative Oncology Group (ECOG) performance status = 1

7. Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

1. Patients who have received chemotherapy, radiotherapy, immunotherapy, or
investigational agents within 4 weeks prior to starting study drug or who have not
recovered from side effects of prior therapies

2. Patients who have had prior exposure to BAL101553.

3. Inability to swallow oral medication.

4. Patients with gastrointestinal disease.

5. Patients with malignant primary brain tumors.

6. Symptomatic brain metastases or leptomeningeal disease, indicative of active disease.

7. Peripheral neuropathy = CTCAE grade 2.

8. Uncontrolled intercurrent illness that would unduly increase the risk of toxicity or
limit compliance with study requirements

9. Systolic blood pressure (SBP) = 140 mmHg or diastolic blood pressure (DBP) = 90 mmHg
at the screening visit.

10. Blood pressure (BP) combination treatment with more than two antihypertensive
medications.

11. Women who are pregnant or breast-feeding. Men or women of reproductive potential who
are not willing to apply effective birth control